Table 1 Patient characteristics

 Age

72.0 [68.0, 74.8]

68.4 ± 7.6^a

66.6 ± 8.1^a

 Gender (male/female)

24/6

62/14

507/131

 Current or former smoker (%)

26 (86.7%)

66 (86.8%)

464 (72.7%)

  Body weight (kg)

54.9 [49.7, 64.4]

63.8 ± 11.6^a

79.2 ± 16.6^a

  Body mass index

21.0 [19.0, 23.6]

24.4 ± 3.4^a

28.1 ± 4.6^a

  Body surface area (DuBois, m²)

1.59 [1.48, 1.72]

–

–

  Prednisolone (%)

3 (10.0%)

9 (11.8%)

136 (21.3%)

  Tacrolimus (%)

1 (3.3%)

0

0

  Aspartate aminotransferase (IU/L)

21.5 [18.0, 24.8]

–

–

  Alanine aminotransferase (IU/L)

16.0 [11.0, 24.3]

–

–

  Total bilirubin (mg/dL)

0.50 [0.30, 0.60]

–

–

  γ-glutamyl transpeptidase (IU/L)

31.0 [21.3, 48.0]

–

–

  Creatinine (mg/dL)

0.80 [0.68, 0.87]

–

–

  Krebs von den Lungen-6 (U/mL)

1021 [829, 1903]

–

–

  Surfactant protein D (ng/dL)

382 [259, 452]

–

–

 Forced vital capacity (L)

1.68 [1.34, 1.99]

2.42 ± 0.67^a

2.71 ± 0.76^a

  % Forced vital capacity (%)

52.9 [43.7, 69.7]

80.9 ± 16.6^a

79.7 ± 17.6^a

 % DLco (%)

44.2 [40.9, 58.5]

44.6 ± 11.4^a

47.4 ± 13.5^a

 Administration period (months)

8.30 [4.23, 13.9]

–

–

 Time from discontinuation to nintedanib initiation

  0 (direct switch)

20 (66.6%)

–

–

  < 1 month

3 (10.0%)

–

–

  ≥ 1 month

7 (23.3%)

–

–

  Decline of FVC

15 (50.0%)

–

–

 Adverse events

15 (50.0%)

–

–

  < 1200 mg

10 (33.3%)

–

–

  1200 mg

16 (53.3%)

–

–

  1800 mg

4 (13.3%)

–

–